Zobrazeno 1 - 10
of 213
pro vyhledávání: '"Nithya Ramnath"'
Autor:
Rishindra M. Reddy, MD, MBA, Kiran Lagisetty, MD, Jules Lin, MD, Andrew C. Chang, MD, Abhinav Achreja, PhD, Nithya Ramnath, MD, Deepak Nagrath, PhD, Robert Dickson, MD, Frank Weinberg, MD, PhD
Publikováno v:
JTCVS Open, Vol 17, Iss , Pp 260-268 (2024)
Objectives: Data are scarce on whether the composition of the lung microbiome (extending from the nasopharynx to the peripheral lung tissue) varies according to histology or grade of non–small cell lung cancer. We hypothesized that the composition
Externí odkaz:
https://doaj.org/article/59c63584c6e74e79a049c75aac14a425
Autor:
Alex K. Bryant, Rafael Zamora‐Resendiz, Xin Dai, Destinee Morrow, Yuewei Lin, Kassidy M. Jungles, James M. Rae, Akshay Tate, Ashley N. Pearson, Ralph Jiang, Lars Fritsche, Theodore S. Lawrence, Weiping Zou, Matthew Schipper, Nithya Ramnath, Shinjae Yoo, Silvia Crivelli, Michael D. Green
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Purpose Real world evidence is crucial to understanding the diffusion of new oncologic therapies, monitoring cancer outcomes, and detecting unexpected toxicities. In practice, real world evidence is challenging to collect rapidly and compreh
Externí odkaz:
https://doaj.org/article/24564ba419ab4b8aac5c0b927356a621
Autor:
Katherine I. Zhou, MD, PhD, Chenyu Lin, MD, Chin-Lin Tseng, MPH, Nithya Ramnath, MBBS, Jonathan E. Dowell, MD, Michael J. Kelley, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 5, Pp 100670- (2024)
Introduction: The KRAS G12C inhibitor sotorasib was approved for treating advanced NSCLC in the second line or later on the basis of the CodeBreaK100 trial. Nevertheless, data on the real-world efficacy and safety of sotorasib, and to its optimal dos
Externí odkaz:
https://doaj.org/article/4f1e08331e2f48cd94d301fa4fe9842e
Autor:
Cindy Y. Jiang, Lili Zhao, Michael D. Green, Shashidhar Ravishankar, Andrea M. H. Towlerton, Anthony J. Scott, Malini Raghavan, Matthew F. Cusick, Edus H. Warren, Nithya Ramnath
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Immune checkpoint inhibitors (ICI) are important treatment options for metastatic non-small cell lung cancer (mNSCLC). However, not all patients benefit from ICIs and can experience immune-related adverse events (irAEs). Limited understandin
Externí odkaz:
https://doaj.org/article/24bd8b92f8cc47e3ab5cc15afdd398f4
Autor:
Emma Purcell, Zeqi Niu, Sarah Owen, Madeline Grzesik, Abigail Radomski, Anna Kaehr, Nna-Emeka Onukwugha, Heather Fairbairn Winkler, Nithya Ramnath, Theodore Lawrence, Shruti Jolly, Sunitha Nagrath
Publikováno v:
Cell Reports, Vol 43, Iss 2, Pp 113687- (2024)
Summary: Circulating tumor cells (CTCs) are early signs of metastasis and can be used to monitor disease progression well before radiological detection by imaging. Using an ultrasensitive graphene oxide microfluidic chip nanotechnology built with gra
Externí odkaz:
https://doaj.org/article/22edef97cc344077b92f9687d1846b85
Autor:
Angel Qin, Fatima Lima, Samantha Bell, Gregory P. Kalemkerian, Bryan J. Schneider, Nithya Ramnath, Madelyn Lew, Santhoshi Krishnan, Shariq Mohammed, Arvind Rao, Timothy L. Frankel
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Immune checkpoint inhibitors (ICI) with anti-PD-1/PD-L1 agents have improved the survival of patients with metastatic non-small cell lung cancer (mNSCLC). Tumor PD-L1 expression is an imperfect biomarker as it does not capture the complex in
Externí odkaz:
https://doaj.org/article/f435bef8f669404c8f0563c60a4c6624
Autor:
David G. Coffey, Yuexin Xu, Andrea M. H. Towlerton, Marcin Kowanetz, Priti Hegde, Martine Darwish, Mahesh Yadav, Craig Blanchette, Shannon M. Ruppert, Sarah Bertino, Qikai Xu, Andrew Ferretti, Adam Weinheimer, Matthew Hellmann, Angel Qin, Dafydd Thomas, Edus H. Warren, Nithya Ramnath
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Most patients with advanced non-small cell lung cancer (NSCLC) do not achieve a durable remission after treatment with immune checkpoint inhibitors. Here we report the clinical history of an exceptional responder to radiation and anti-program death-l
Externí odkaz:
https://doaj.org/article/0ad62252e9ae47dfa7add7911dd39d72
Autor:
Emma Purcell, Sarah Owen, Emily Prantzalos, Abigail Radomski, Nayri Carman, Ting-Wen Lo, Mina Zeinali, Chitra Subramanian, Nithya Ramnath, Sunitha Nagrath
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
In non-small cell lung cancer (NSCLC), identifying the presence of sensitizing and resistance epidermal growth factor receptor (EGFR) mutations dictates treatment plans. Extracellular vesicles (EVs) are emerging as abundant, stable potential liquid b
Externí odkaz:
https://doaj.org/article/f88f5036fc264c2a81eb9c63bb5ee78c
Autor:
Michael D Green, Lili Zhao, Dean E Brenner, Cindy Y Jiang, Zeqi Niu, Shelby Raupp, Brittany Pannecouk, Sunitha Nagrath, Nithya Ramnath
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Immunotherapy for cancer is now a standard pillar in the armamentarium of treatments for many cancers. Immune checkpoint inhibitors, in particular, have resulted in significant therapeutic benefit and prolongation of survival in solid organ cancers,
Externí odkaz:
https://doaj.org/article/a3e7592b2b7b405d94fe4e9945cc66b2
Autor:
Yoon‐Tae Kang, Zeqi Niu, Thomas Hadlock, Emma Purcell, Ting‐Wen Lo, Mina Zeinali, Sarah Owen, Venkateshwar G. Keshamouni, Rishindra Reddy, Nithya Ramnath, Sunitha Nagrath
Publikováno v:
Advanced Science, Vol 8, Iss 6, Pp n/a-n/a (2021)
Abstract As the recognition between natural killer (NK) cells and cancer cells does not require antigen presentation, NK cells are being actively studied for use in adoptive cell therapies in the rapidly evolving armamentarium of cancer immunotherapy
Externí odkaz:
https://doaj.org/article/1fe86000dcdb48de8238d16d2b30f982